Uterine Corpus Leiomyosarcoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Uterine Corpus Leiomyosarcoma	No biomarker	Uterine Corpus Leiomyosarcoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
AKT1 E17K	Uterine Corpus Leiomyosarcoma	AKT1 E17K	Uterine Corpus Leiomyosarcoma	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
CD70 expression	Uterine Corpus Leiomyosarcoma	CD70 expression	Uterine Corpus Leiomyosarcoma	JNJ-0631 Sensitive: C3 – Early Trials JNJ-0631 Sensitive : C3	JNJ-0631 Sensitive: C3 – Early Trials JNJ-0631 Sensitive : C3
ER positive + PGR positive	Uterine Corpus Leiomyosarcoma	ER positive + PGR positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
PALB2 deletion	Uterine Corpus Leiomyosarcoma	PALB2 deletion	Uterine Corpus Leiomyosarcoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
RAD51B deletion	Uterine Corpus Leiomyosarcoma	RAD51B deletion	Uterine Corpus Leiomyosarcoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
BRCA2 mutation	Uterine Corpus Leiomyosarcoma	BRCA2 mutation	Uterine Corpus Leiomyosarcoma	avelumab + talazoparib Sensitive: C3 – Early Trials avelumab + talazoparib Sensitive : C3	avelumab + talazoparib Sensitive: C3 – Early Trials avelumab + talazoparib Sensitive : C3
BRCA1 mutation	Uterine Corpus Leiomyosarcoma	BRCA1 mutation	Uterine Corpus Leiomyosarcoma	avelumab + talazoparib Sensitive: C3 – Early Trials avelumab + talazoparib Sensitive : C3	avelumab + talazoparib Sensitive: C3 – Early Trials avelumab + talazoparib Sensitive : C3
HRD	Uterine Corpus Leiomyosarcoma	HRD	Uterine Corpus Leiomyosarcoma	olaparib + temozolomide Sensitive: C3 – Early Trials olaparib + temozolomide Sensitive : C3	olaparib + temozolomide Sensitive: C3 – Early Trials olaparib + temozolomide Sensitive : C3
FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	lorlatinib Sensitive: C4 – Case Studies lorlatinib Sensitive : C4	lorlatinib Sensitive: C4 – Case Studies lorlatinib Sensitive : C4
FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4
FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	pazopanib Resistant: C4 – Case Studies pazopanib Resistant : C4	pazopanib Resistant: C4 – Case Studies pazopanib Resistant : C4
BRCA2 mutation	Uterine Corpus Leiomyosarcoma	BRCA2 mutation	Uterine Corpus Leiomyosarcoma	PARP inhibitor Sensitive: D – Preclinical PARP inhibitor Sensitive : D	PARP inhibitor Sensitive: D – Preclinical PARP inhibitor Sensitive : D
ATRX mutation	Uterine Corpus Leiomyosarcoma	ATRX mutation	Uterine Corpus Leiomyosarcoma	BAY 1895344 Sensitive: D – Preclinical BAY 1895344 Sensitive : D	BAY 1895344 Sensitive: D – Preclinical BAY 1895344 Sensitive : D

Uterine Corpus Leiomyosarcoma

Associations(23)

Associations
(23)